This Article Full Text (PDF) References Alert me when this article is cited Alert me if a correction is posted Services Email this article to a friend Similar articles in this journal Alert me to new issues of the journal Add to Saved Citations Download to citation manager Request Permissions Request Reprints Add to My Marked Citations Citing Articles Citing Articles via Google Scholar Citing Articles via Scopus Google Scholar Articles by Kälviäinen, R. Articles by Riekkinen, P. J. Search for Related Content PubMed Articles by Kälviäinen, R. Articles by Riekkinen, P. J. Social Bookmarking                         What's this?

Randomized Controlled Pilot Study of Vigabatrin Versus Carbamazepine Monotherapy in Newly Diagnosed Patients With Epilepsy: An Interim Report

Departments of Neurology and Clinical Neurophysiology, Kuopio University Central Hospital, Kuopio, Finland

Marja Äikiä, MA

Departments of Neurology and Clinical Neurophysiology, Kuopio University Central Hospital, Kuopio, Finland

Juhani Partanen, MD

Departments of Neurology and Clinical Neurophysiology, Kuopio University Central Hospital, Kuopio, Finland

Juhani Sivenius, MD

Departments of Neurology and Clinical Neurophysiology, Kuopio University Central Hospital, Kuopio, Finland

John Mumford, MB, ChB, FFPM

Marion Merrell Dow Research Institute, Winnersh, UK

Markku Saksa, MD

Departments of Neurology and Clinical Neurophysiology, Kuopio University Central Hospital, Kuopio, Finland

Paavo J. Riekkinen, MD

Departments of Neurology and Clinical Neurophysiology, Kuopio University Central Hospital, Kuopio, Finland

At present, 34 patients aged 15 to 63 years with newly diagnosed epilepsy have been randomly assigned to vigabatrin (n = 17) or carbamazepine (n = 17). Evaluation of clinical data, neuropsychological assessment, quantitative spectral electroencephalogram (EEG), and somatosensory- and visual-evoked potentials at baseline and after a 3 months' maintenance phase are presented for 12 patients on vigabatrin and for 11 patients on carbamazepine. Among these patients, retention rate in the maintenance phase of the study is 75% for vigabatrin patients (two noncompliant patients and one nonresponder dropped out) followed up for a mean of 11 months (range, 5 to 16 months). The retention rate for carbamazepine is 100% for the 11 patients, followed up for a mean of 9 months (range, 3 to 17 months). Patients receiving vigabatrin showed significant improvements in sustained concentration and tasks requiring flexible mental processing after the 3-month maintenance period, compared to baseline. In the carbamazepine group, there was improvement only in delayed list recall, and in contrast, errors in visuomotor tasks requiring processing increased significantly. Patients on carbamazepine demonstrated slowed occipital mean frequencies, but vigabatrin treatment was not associated with any significant quantitative EEG changes. Significant prolongation of somatosensory-evoked potential N19 latencies was seen with both carbamazepine and vigabatrin. (J Child Neurol 1991;6(Suppl):2S60-2S69).

Journal of Child Neurology, Vol. 6, No. 2 Suppl, 2S60-2S69 (1991)
DOI: 10.1177/0883073891006002111


CiteULike    Complore    Connotea    Del.icio.us    Digg    Reddit    Technorati    Twitter    What's this?